Close Menu

Clostridium difficile

A group led by Mount Sinai researchers said this methyltransferase, which is involved in sporulation, could be targeted to fight infections.

The firm's tick-borne pathogens panel was also recently the subject of a clinical study, showing high accuracy in detecting numerous infectious agents. 

Based in Warsaw, Poland, the technology was inspired by "ultra-fast" PCR methods from the Wittwer group and Scope plans to launch tests for MRSA and C. diff.

An analysis of more than 900 C. difficile isolates uncovered four phylogenetic lineages, including three lineages in a clade showing recent positive selection on infection-related genes.

The firm aims to stabilize and protect its existing molecular diagnostics business over the next 12 to 18 months, CEO Jack Kenny said.

The four-year loan will be used to develop molecular diagnostic assays for the firm's two test systems, Amplidiag and Novodiag.

Cincinnati, Ohio-based Meridian will acquire Quebec City-based GenePOC for $120 million, and hopes to quickly convert customers to a PCR-based instrument.

A Drug or What?

The FDA has yet to determine if fecal microbiome transplants should be treated like a drug or like a blood transfusion, the New York Times reports.

Signature Science will assess the validity of metagenomic and metatranscriptomic analyses to detect the transmission of viable pathogens in healthcare settings.

Researchers hope that understanding the etiology of inappropriate testing will help them design a better computerized support tool.

Pages

Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing. 

Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.

Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports. 

In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.